Vertex Pharmaceuticals Incorporated
VRTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 4.22 | 0.46 | -1.66 | -2.30 |
| FCF Yield | 1.14% | 0.81% | 0.62% | 0.47% |
| EV / EBITDA | 74.49 | 82.81 | 155.44 | 85.17 |
| Quality | ||||
| ROIC | 4.85% | 4.66% | 2.92% | 4.32% |
| Gross Margin | 86.52% | 86.25% | 86.90% | 85.46% |
| Cash Conversion Ratio | 1.15 | 1.04 | 1.27 | 0.64 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.69% | 6.31% | 6.43% | 7.25% |
| Free Cash Flow Growth | 22.88% | 19.17% | 58.17% | -62.21% |
| Safety | ||||
| Net Debt / EBITDA | -2.38 | -2.57 | -3.87 | -2.38 |
| Interest Coverage | 359.45 | 311.11 | 210.03 | 366.43 |
| Efficiency | ||||
| Inventory Turnover | 0.25 | 0.27 | 0.27 | 0.35 |
| Cash Conversion Cycle | -465.31 | 290.93 | 285.43 | 218.18 |